Cue Biopharma (CUE)

NASDAQ
10.42
-0.21(-1.98%)
  • Volume:
    117,800
  • Bid/Ask:
    10.36/10.45
  • Day's Range:
    10.24 - 10.63

CUE Overview

Prev. Close
10.63
Day's Range
10.24-10.63
Revenue
3.8M
Open
10.49
52 wk Range
9.86-22.49
EPS
-1.5
Volume
117,800
Market Cap
327.32M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
440,052
P/E Ratio
-
Beta
1.76
1-Year Change
-44.9%
Shares Outstanding
31,412,841
Next Earnings Date
Aug 16, 2021
What is your sentiment on Cue Biopharma?
or
Market is currently closed. Voting is open during market hours.

Cue Biopharma News

Cue Biopharma Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuySellStrong SellStrong Sell
SummaryStrong BuyBuySellStrong SellStrong Sell

Cue Biopharma Company Profile

Cue Biopharma Company Profile

Employees
51

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 would also leverage the IL-2 based CUE-100 framework and target an antigen to be selected in collaboration with LG Chem; CUE-200 framework that utilizes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences to the development of Immuno-STATs focused in the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Read More
  • this expletive company... years and years of promoses. still nothing
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.